Case Studies
Strategic Portfolio Expansion
and Partnership Development
Introduction
A specialty pharmaceutical company from Canada sought to expand its portfolio by identifying innovative prescription products aligned with its focus on neurodegenerative diseases. To achieve this, the company engaged Trifermed to support its search for high-value pharmaceutical assets and to facilitate strategic partnerships for licensing agreements.
Through Trifermed’s structured approach to portfolio development and strategic partnerships, the company successfully identified and secured an agreement for a novel treatment option for Parkinson’s Disease with a European pharmaceutical company specializing in central nervous system (CNS) disorders. This collaboration positioned the Canadian company as a key player in the Canadian Parkinson’s treatment landscape.
Background
Parkinson’s Disease affects an estimated 100,000 Canadians, with the prevalence expected to rise significantly in the coming decades. The company aimed to address the growing need for innovative treatments by acquiring a product that would complement its existing portfolio and enhance its market presence in Canada.
The primary objectives were:
Identifying high-potential pharmaceutical assets in the CNS therapeutic area.
Establishing a licensing agreement with a reputable partner for market expansion.
Ensuring a structured negotiation process leading to a mutually beneficial partnership.
Trifermed was engaged to facilitate this process by leveraging its expertise in business development, portfolio strategy, and partnership negotiation.
Our Approach
Trifermed applied its proprietary methodology to ensure a successful asset identification and partnership negotiation:
Portfolio Analysis & Strategic Planning
Conducted an in-depth review of the client’s existing portfolio and strategic priorities.
Defined key selection criteria for potential pharmaceutical assets based on market needs and regulatory feasibility.
Market Intelligence & Asset Scouting
Performed a comprehensive market scan to identify innovative pharmaceutical products in the CNS space.
Evaluated clinical, regulatory, and commercial viability of potential assets.
Partner Identification & Negotiation Support
Identified leading pharmaceutical companies with relevant expertise in neurodegenerative diseases.
Managed discussions between the client and the European partner to align expectations and define key terms.
Structured a licensing agreement ensuring long-term collaboration and product success in the Canadian market.
Services Provided
Portfolio Strategy & Asset Identification
Market Intelligence & Asset Scouting
Partner Identification & Negotiation Support
Outcomes & Future Development
As a result of Trifermed’s facilitation, the Canadian company successfully secured exclusive rights to commercialize the Parkinson’s treatment in Canada. The licensing agreement enabled:
Portfolio Expansion: Strengthening the company’s presence in the CNS market with an innovative Parkinson’s therapy.
Strategic Growth: Enhancing the company’s competitive positioning within Canada’s neurodegenerative disease sector.
Market Readiness: Ensuring a smooth transition from regulatory approval to commercialization through a structured partnership framework.
With this agreement in place, the company is well-positioned to drive growth in the Parkinson’s treatment space while continuing to explore additional opportunities for portfolio expansion.